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Derived from arachidonic acid, epoxyeicosatrienoic acids
function as antihypertensive and antihypertrophic mediators
in the cardiovascular system. Epoxyeicosatrienoic acids are
generated by soluble epoxide hydrolase, an enzyme
hydrolyzing the epoxide moiety of juvenile hormones in
insects, and are endothelium-derived hyperpolarizing factors
that induce vessel dilation for cardioprotection.
Pharmacological inhibition and genetic ablation of soluble
epoxide hydrolase increases the level of epoxyeicosatrienoic
acids. Recent findings suggest that the level of soluble
epoxide hydrolase in the heart and endothelium is
upregulated by angiotensin II in vitro in cultured
cardiomyocytes and vascular endothelial cells and in vivo in
rodent models. Treatment with soluble epoxide hydrolase-
selective inhibitors in angiotensin II–infused hypertensive
rats increases the level of epoxyeicosatrienoic acids, with
attendant decrease in systolic blood pressure. Shear stress,
the physiological stimulation of vessel dilation,
downregulates soluble epoxide hydrolase and hence
increases epoxyeicosatrienoic acid level in endothelial cells.
Because of the close association of the angiotensin II/soluble
epoxide hydrolase/epoxyeicosatrienoic acid system and
blood pressure regulation, pharmacological inhibition of
soluble epoxide hydrolase would be a useful approach to
prevent and treat angiotensin II–induced cardiac
hypertrophy and hypertension, as well as vascular
impairments.
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Epoxide hydrolase (EH) was originally identified as an
enzyme hydrolyzing the epoxide moiety of juvenile hormones
in all insects. EH orthologs, including soluble epoxide
hydrolase (sEH), microsomal EH, cholesterol EH, hepoxilin
hydrolase and leukotriene A4 hydrolase, are found in
mammalian cells. Among them, sEH is composed of two
62-kDa monomeric subunits and mainly localized in the
cytosol. The C-terminal region of mammalian sEH
contains the catalytic domain that hydrolyzes epoxyeicosa-
trienoic acids (EETs) to result in the corresponding diols,
dihydroxyeicosatrienoic acids.1 The catalysis of sEH involves
the formation and hydrolysis of a covalent acylor alkyl-
enzyme intermediate. sEH is distributed in various tissues,
including the liver, kidney, lungs, heart, brain, spleen,
vascular endothelium and smooth muscle, skin, and
leukocytes.1
EETs, derived from arachidonic acid, are recognized as
major regulators of renal and cardiovascular function.
Although arachidonic acid is catabolized by three pathways
(that is, cytochrome P450 epoxgenases (CYP), cyclooxy-
genases, and lipoxygenases), CYP2C and CYP2J are the two
major human CYP isoforms that convert arachidonic acid to
5,6-, 8,9-, 11,12-, or 14,15-EET (Figure 1). CYP2C and CYP2J
can produce all four EET regioisomers, but 11,12- and 14,15-
EETs are the predominant products.1 In mammals, EETs
are considered endothelium-derived hyperpolarizing factors
that lead to vasodilation in a number of vascular beds. The
involved mechanism is EETs activating the large-conductance
Ca2þ -activated Kþ channels in vascular smooth muscle
cells and thus rendering them hyperpolarized.2 Independent
of their membrane-hyperpolarizing effects, EETs exert
anti-inflammatory effects in vascular endothelial cells
(ECs) by a mechanism involving inhibition of the transcrip-
tion factor NF-kB.3 EETs also show potent effects on
renal vascular reactivity and tubular sodium and water
transport.
The enzyme sEH, through hydrolyzing EETs, has a similar
effect on cardiac hypertrophy as that by angiotensin II
(Ang II).4 Because of the vasodilating effect of EETs, sEH may
also mediate the vasoconstriction effect induced by Ang II.
This review summarizes recent findings on the association of
sEH and Ang II in the cardiovascular system.
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ANG II, BLOOD PRESSURE, AND sEH INHIBITION
Acting at distinct anatomic sites, Ang II is the main effector
peptide in the renin–angiotensin–aldosterone system that
maintains systemic blood pressure. Ang II also has a
detrimental role in cardiovascular impairments such as
hypertension, cardiac hypertrophy, and atherosclerosis.
Several recent studies of rodent models demonstrated a
positive association of sEH, Ang II, and elevated blood
pressure. Yu et al.5 demonstrated that EET hydrolysis greatly
increased the renal cortical fractions of spontaneously
hypertensive rats (SHRs) as compared with normotensive
Wistar–Kyoto rats. This augmented EET hydrolysis was
consistent with increased expression of sEH in SHR renal
microsomes and cytosol. The administration of 1,3-dicyclo-
hexyl urea, the first generation of competitive sEH inhibitors,
significantly lowered blood pressure in these animals. Imig’s
group6,7 showed increased sEH protein expression in the
kidney and renal microvessels of rats treated with Ang II.
Treating these animals with another sEH inhibitor,
1-cyclohexyl-3-dodecyl urea (CDU, also known as NCND),
decreased blood pressure and urinary albumin excretion and
reduced the diameter response to Ang II of the afferent
arteriole in the hypertensive rats.6,7 Fleming’s group showed
that pre-treating animals with a water-soluble sEH inhibitor,
12-(3-adamantan-1-yluredio) dodecanoic acid (AUDA), lar-
gely attenuated the hypertensive effect of Ang II. Convin-
cingly, the cessation of AUDA treatment increased the blood
pressure, which reached the level of the AUDA-untreated
hypertensive animals; when AUDA treatment was started
again after induction of Ang II-induced hypertension, blood
pressure dropped almost to the basal level.8 The sEH
inhibitor could also lower blood pressure and ameliorate
renal damage in Ang II-infused and high salt-fed rats.9
Collectively, these studies suggest that an elevated level of
Ang II is associated with increased expression of sEH in
blood pressure-regulating tissues and increased systemic
blood pressure. Inhibitors of sEH could be used as
therapeutic agents for Ang II- and salt-dependent hyperten-
sion. The exact mechanism by which various sEH inhibitors
exert antihypertensive effects is unclear. Blood pressure
lowering may be the result of EETs’ initial reduction of
cardiac rates, followed by pressure diuresis resulting from
increased perfusion of the kidney.8 However, a reduction in
heart rate was not observed in rats when sEH inhibitors were
administered chronically.6 Alternatively, sEH inhibitors may
enhance the vasodilatation effect of EETs on resistant arteries.
The addition of EETs or overexpression of P450 epoxygenases
in vivo and in vitro resulted in increased expression and
activation of eNOS, which suggests that EETs can influence
the vascular NO level.10 Recently, Hercule et al.11 used
N-adamantyl-N0-dodecylurea to show that EETs/dihydroxy-
eicosatrienoic acids induce endothelial NO release to
modulate vascular tone in isolated mesenteric arteries. In
that study, the eicosanoids seemed to work by their ability to
stimulate NO release.
In addition to regulating blood pressure, sEH may be
involved in inflammation. Recent study showed that
Ang II- and high-salt diet-induced hypertension in diabetic
Goto–Kakizaki rats increased urinary albumin excretion and
glomerular and tubular damage. Although the administration
of AUDA did not alter blood glucose and blood pressure in
the hypertensive Goto–Kakizaki rats, glomerular and tubular
damage were decreased. In addition, AUDA treatment
attenuated macrophage infiltration and urinary excretion of
albumin and monocyte chemoattractant protein-1, which
might be due in part to the decreased expression of monocyte
chemoattractant protein-1 in the kidney cortex.12
THE REGULATION OF sEH BY ANG II IN ECs
Given that EETs have a beneficial effect on vasculature and
that sEH can hydrolyze EETs to attenuate vasodilation and
anti-inflammatory effects, Ang II may regulate sEH expres-
sion and/or activity in the vasculature. Expression of sEH was
found to be increased in the renal microvessels of Ang II-
induced hypertensive rats.6 In addition, we showed an
increased protein level of sEH in aortic specimens collected
from saline-fed SHRs and Ang II-infused Wistar–Kyoto
rats.13 Angiotensin type 1 receptor (AT1) blocker (that is,
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Figure 1 |Arachidonic acid (AA) is generated by the catalysis
of phospholipase A2 (PLA2) from membrane phospholipids.
AA is converted to many metabolic products. Although
epoxyeicosatrienoic acids (EETs) are formed by cytochrome P450,
cyclooxygenases (COXs) convert AA to prostanoids, and
lipoxygenases (LOXs) generate leukotrienes and prostaglandins.
CYP2C and CYP2J are the two major human CYP isoforms that
convert AA to 5,6-, 8,9-, 11,12-, or 14,15-EET. Soluble epoxide
hydrolase (sEH) converts the EETs to their corresponding
less-active diols, dihydroxyeicosatrienoic acids. CYP, cytochrome
P450 epoxgenases.
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losartan) abrogated the increased sEH protein level induced
by Ang II, which suggests that the effect was mediated
through the AT1 receptor. It is interesting to note that the
sEH level was increased in the aortic intima, which is
composed of endothelium, but not in the media, which
contains mainly vascular smooth muscle cells. In cultured
ECs, the expression of sEH at both the protein and mRNA
levels was greatly increased by Ang II in a dose- and time-
dependent manner. A promoter transfection study further
confirmed that the regulation of sEH by Ang II is at the level
of transcription.13
As a potent mitogen, Ang II binds to its receptor, AT1, to
activate several signaling pathways, with consequent upregu-
lation of downstream transcriptional factors, including
NF-kB, activator protein 1 (AP-1), nuclear factor of activated
T-cell and signal transducers and activators of transcription,
which govern the targeting genes in Figure 2. Among them,
sEH is a novel targeting gene regulated by Ang II. Sequence
analysis revealed one NF-kB-binding site and three AP-1
putative binding sites in the cloned 1.1-kb human sEH
promoter. Although Ang II activates both NF-kB and AP-1,
the AP-1 site at 446 of the sEH promoter seems to be
responsible for the induction of sEH by Ang II. Furthermore,
overexpressing c-Jun and its dominant-negative mutant
confirmed that c-Jun is necessary and sufficient for sEH
induction by Ang II.13 Recently, Monti et al.14 identified sEH
as a gene related to heart failure susceptibility in rats with
spontaneously hypertensive heart failure. Upstream sequen-
cing analysis revealed a 2-nt deletion in the putative sEH
promoter in rats with spontaneously hypertensive heart
failure as compared with SHRs and Wistar–Kyoto rats.
Interestingly, the 2-nt promoter deletion creates an AP-1-
binding site in rats with spontaneously hypertensive heart
failure. This AP-1-binding site may contribute to increased
transcriptional activation, protein expression, and enzyme
activity, leading to more rapid hydrolysis of cardioprotective
EETs and further suggests the importance of AP-1 in sEH
regulation. Thus, binding of Ang II to the AT1 receptor may
activate a series of signaling cascades, which in turn, may
activate AP-1 to bind to the cognate cis-element at the
promoter of the sEH gene. The increased sEH level therefore
enhances the hydrolysis of EETs to become dihydroxyeicosa-
trienoic acids. With decreased level of EETs released from
ECs, the paracrine effect of EETs on VSMC hyperpolarization
is attenuated, which then increases blood pressure (depicted
in Figure 3).
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Figure 2 |Overview of the signal transduction pathways stimulated by angiotensin II (Ang II) in the cardiovascular system.
Ang II binds to angiotensin type 1 receptor (AT1) to activate several signaling pathways, with consequent upregulation of the downstream
transcriptional factors, including nuclear factor (NF)-kB, activating protein 1 (AP-1), nuclear factor of activated T-cell (NFAT), and signal
transducers and activators of transcription (STATs). Each transcriptional factor governs its targeting genes as listed. sEH is transcriptionally
upregulated by the AP-1 pathway. All these genes contribute to the effects of Ang II, including vasoconstriction, vascular inflammation, cell
proliferation, myocardial hypertrophy, fibrosis, and renal damage. Because sEH inhibitors can ameliorate most effects induced by Ang II, sEH
has an important role in the function of Ang II in the cardiovascular system. sEH, soluble epoxide hydrolase.
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IMPLICATION OF sEH DOWNREGULATION IN VASCULAR
IMPAIRMENT
Shear stress, the tangential component of hemodynamic
forces acting on the endothelium, is a physiological
stimulation leading to an increase in the bioavailability of
endothelial nitric oxide synthase (eNOS)-derived NO.
Because EETs have an endothelium-dependent hyperpolariz-
ing effect and shear stress causes vessel dilation, we have
examined whether shear stress regulates the level of EETs and
sEH in ECs. Shear stress augmented cellular levels of EETs,
but decreased the mRNA and protein levels and activity of
sEH.15 Competition and direct binding assays showed that
EETs bind to the ligand-binding domain of the nuclear
receptor peroxisome proliferator-activated receptor g
(PPARg) with kilodaltons in the micromolar range. In the
presence of AUDA, EETs increased PPARg transcriptional
activity in ECs. These findings suggest that EETs are PPARg
ligands, which is in line with a previous report that shear
stress increased the transcriptional activity of PPARg
in ECs.16 Indeed, inclusion of AUDA in the perfusing
media enhanced but overexpression of sEH reduced the
laminar flow-induced PPARg activity.15 Mounting evidence
has revealed the anti-inflammatory effect of PPARg and its
cognate ligand thiazolidinedione in the cardiovascular
system. Shear stress downregulation of sEH in ECs strongly
suggests the involvement of the sEH/EET system in vascular
integrity.
sEH inhibitors were found to decrease the formation of
atherosclerotic lesions. Descending aortas from apolipopro-
tein E-null mice fed an atherogenic diet while simultaneously
infused with Ang II and an sEH inhibitor showed a 53%
reduction in atherosclerotic lesions as compared with control
aortas. The reduction in atherosclerosis was inversely
associated with ratios of 11,12- and 14,15-EET to DHET,
which suggests that the reduction in lesions was associated
with the inhibition of sEH.17
ANG II, sEH, AND CARDIAC HYPERTROPHY
Attenuated sEH level and/or activity, with attendant increase
in the level of EETs, appears to be beneficial to the heart.
Ablation of the mouse sEH gene protects these animals
against pressure overload-induced heart failure and cardiac
arrhythmias.14 In contrast, an augmented level of sEH with
consequent decrease in EETs may be pathophysiological.
We found sEH level increased in myocardia collected from
saline-fed SHRs or Ang II-infused Wistar rats.4 A newly
developed sEH inhibitor, 1-(1-methanesulfonyl-piperidin-
4-yl)-3- (4-trifluoromethoxy-phenyl) urea (TUPS, 1709),
could significantly attenuate the hypertrophic phenotype
induced by Ang II, as seen in the ratio of heart to body weight
and ventricular thickness. The impressive effect of TUPS may
due to its potent urea pharmacophore, excellent oral
availability and pharmacokinetic properties. In a canine
model, TUPS showed good absorption, distribution, meta-
bolism, and excretion, with very low IC50.
18 In our study, we
focused on the effect of TUPS on the heart; TUPS may also
have a protective effect on Ang II-induced renal injury.
Although cardiac hypertrophy can result from physio-
logical exercise, mechanical overload, and/or neurohormonal
factors, the mechanisms leading to hypertrophy during
pathologic and physiologic states are distinct. The applica-
tion of AUDA was found to lower blood pressure and heart
rate in animals with Ang II-induced hypertension but failed
to affect blood pressure in animals with phenylephrine-
induced hypertension.8 Consistently, we found sEH expres-
sion upregulated in the Ang II-induced pathologic state
but not with norepinephrine treatment or exercise.4 The
protein level of sEH did not significantly change in mice
with hypertrophy induced by transverse aortic constriction,
but an sEH inhibitor could prevent cardiac enlargement.19
NF-kB activation was inhibited by an sEH inhibitor in this
hypertrophy model.19 but the transcriptional upregulation of
sEH by Ang II seems mainly via AP-1, which contributes to
the pathological outcome of Ang II-induced cardiac hyper-
trophy.4
In vitro, Ang II upregulated sEH and hypertrophy markers
in neonatal cardiomyocytes isolated from rat and mouse.
The expression of these marker genes was elevated with
Ang II Iosartan
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Figure 3 | The binding of Ang II to its receptor AT1 activates
AP-1 and increases the binding of AP-1 to the cognate
cis-element in the sEH promoter to enhance the expression
of sEH. The increased sEH promotes the hydrolization of more
EETs into dihydroxyeicosatrienoic acids (DHETs). With decreased
EETs released from endothelial cells, the paracrine effect of EETs
on vascular smooth muscle cell hyperpolarization is attenuated,
which increases blood pressure. Ang II, angiotensin II; AP-1,
activating protein 1; AT1, angiotensin type 1 receptor; EETs,
epoxyeicosatrienoic acids; sEH, soluble epoxide hydrolase.
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adenovirus-mediated sEH overexpression but decreased with
sEH inhibition or in neonatal cardiomyocytes from sEH/
mice. At the molecular level, Batchu et al.20 reported that
EETs enhanced the recovery of ventricular repolarization
following ischemia, possibly through the activation of Kþ
channels and protein kinase A-dependent signaling.
CONCLUSION AND PERSPECTIVES
The above summary of the literature suggests that an above
physiological level of Ang II is associated with elevated
expression and/or increased activity of sEH in cardiovascular
cells in vivo and in vitro. Presumably, the binding of Ang II to
AT1 elicits intracellular signaling to promote the transcrip-
tional activation of sEH through AP-1. The detailed
molecular signaling and the co-activators and co-repressors
involved deserve future study. Because EETs are cardiovas-
cular protective, the pathological consequences of the
induction of sEH by Ang II would be a decreased level of
EETs. Given the four regioisomers of EETs, the specificity of
each serving as the substrate of sEH and the mechanisms by
which they protect ECs and cardiomyocytes are other
possible research topics. In addition, eNOS-derived NO
bioavailability is pivotal for the physiological functions of the
cardiovascular system; the interaction of Ang II, sEH, and
EET merges with the eNOS/NO pathway to modulate
vasomotor tone and blood pressure. More information is
needed on this interaction and its implications during
cardiovascular disease.
The potency of the Ang II/sEH system in modulating
blood pressure and the associated cardiovascular impair-
ments suggest the possibility of sEH inhibitors used as
pharmacological therapy for hypertension and other Ang II-
related cardiovascular diseases. From knowledge of the
mechanism of sEH catalysis, transition state inhibitors such
as 1,3-dicyclohexyl urea and ACU have been developed.
Although potent, these inhibitors are difficult to formulate
for delivery.18 Newer versions of sEH inhibitors with
improved solubility, including AUDA and TUPS, have been
used in animal experiments and show clinical efficacy.
Actually, results for the first orally administered sEH
inhibitor, AR9281, investigated in a phase I clinical trial in
healthy volunteers, has recently been reported (http://
www.aretetherapeutics.com/news/2008/121808.html). Future
research could investigate the clinical applications of various
sEH inhibitors in hypertension, metabolic syndrome, and
several inflammatory disorders.
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